Dec 29, 2025 11:25AM Jefferies on Inhibikase Therapeutics Inc (IKT): 'the stock at $200-250M cap is inexpensive'

Dec 26, 2025 06:41AM H.C. Wainwright Assumes Inhibikase Therapeutics Inc (IKT) at Buy

Dec 11, 2025 08:04AM Cantor Fitzgerald Starts Inhibikase Therapeutics Inc (IKT) at Overweight

Nov 14, 2025 05:36PM Inhibikase Therapeutics (IKT) Misses Q3 EPS by 13c

Aug 19, 2025 08:03AM Inhibikase appoints Timothy Pigot as chief commercial and strategy officer

Aug 15, 2025 07:19AM Inhibikase Therapeutics (IKT) Misses Q2 EPS by 11c

Jun 20, 2025 05:08PM Inhibikase Therapeutics (IKT) Files $300M Mixed Shelf

May 15, 2025 05:40PM Inhibikase Therapeutics (IKT) Misses Q1 EPS by 15c

Apr 14, 2025 08:00AM Inhibikase Therapeutics (IKT) Announces Appointment of David McIntyre as Chief Financial Officer

Mar 31, 2025 06:45AM H.C. Wainwright Reiterates Neutral Rating on Inhibikase Therapeutics Inc (IKT)

Feb 24, 2025 08:02AM Inhibikase Therapeutics (IKT) Announces Expansion of Senior Leadership Team

Feb 18, 2025 08:00AM Inhibikase Therapeutics (IKT) Appoints Mark Iwicki as CEO

Nov 14, 2024 05:23PM Inhibikase Therapeutics (IKT) Misses Q3 EPS by 65c

Nov 8, 2024 03:22AM Jefferies Starts Inhibikase Therapeutics Inc (IKT) at Buy

Oct 14, 2024 06:46AM Inhibikase Therapeutics Inc (IKT) PT Lowered to $5 at H.C. Wainwright

Oct 9, 2024 09:19AM Inhibikase Therapeutics (IKT) Prices $110M Private Placement to Advance IkT-001Pro

Aug 16, 2024 06:44AM Inhibikase Therapeutics Inc (IKT) PT Lowered to $15 at H.C. Wainwright